BlueWillow Biologics Stock
BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company.
Sign up today and learn more about BlueWillow Biologics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About BlueWillow Biologics Stock
BlueWillow Biologics operates as a clinical-stage privately-held biopharmaceutical company. It focuses on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. Its platform employs novel oil-in-water nano-droplets for products administered to the skin and nose. The company was founded as a spin-off from the University of Michigan and is headquartered in Ann Arbor, Michigan.
Funding History
| October 2006 | $30.0M |
|---|---|
| February 2009 | $12.0M |
| July 2009 | $10.0M |
| November 2010 | $6.0M |
| November 2012 | $11.0M |
| October 2013 | $5.5M |
| February 2016 | $1.8M |
| May 2018 | $10.0M |
Management
Sr. Vice President, Vaccine Research & Development
Ali I. Fattom
Member Of The Board Of Directors
Robert C. Moellering
Sr. Vice President, Development
Lyou-Fu Ma
Founder
James R Baker
Member Of The Board Of Directors
Peter G. Ulrich
Member Of The Board Of Directors
David M. Stout
Vice President, Clinical Research
Mary R. Flack
Member Of The Board Of Directors
Anjali V. Jolly
Vice President, Regulatory Affairs
Stephen Gracon
Member Of The Board Of Directors
Ronald M. Cresswell
Press
patents - Apr, 16 2024
Herpes simplex virus nanoemulsion vaccines and methods of using the samepatents - Apr, 16 2024
Persistant topical antimicrobial compositions and methods of using the samepatents - Apr, 16 2024
Persistant topical antimicrobial compositions and methods of using the samepatents - Apr, 16 2024
Intranasal polysaccharide conjugate nanoemulsion vaccines and methods of using …patents - Apr, 16 2024
Nanoemulsion universal influenza vaccineEquityZen Recognized As:
